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Aim. In this study we presented our experience of 18 years on the etiology, risk factors, prophylactic and acute treatment, the
eﬀect of treatment to recurrence rate of patients with stroke. Methods. The population included 108 patients who had been treated
for stroke at Pediatric Neurology Department of Ankara University with the diagnosis of arterial ischemic stroke and sinovenous
thrombosis between January 1992 and August 2010. Forty-one girls (38%) and 67 boys (62%) with mean symptom age 3.1 ±4.04
years,(0–18yearsold)werefollowedupwithameanperiodof4.9±3.78years(0–17years).Results.30patientshadnoriskfactors,
34 patients had only one risk factor and 44 patients had multiple risk factors. Recurrence was seen in three patients. There was no
any statistical correlation between the recurrence of stroke and the existence of risk factors (P = .961). Seventeen patients received
prophylactic treatment; 2 of them without any risk factors, 3 had one risk factor, 12 patients, who constituted the majority of our
patients, had multiple risk factors (P = .024). Conclusion. With this study we showed that the right prophylaxis for right patients
reduces the rate of recurrence.
1.Introduction
In recent years, the incidence for paediatric stroke has rea-
ched up to 8 per 100,000 children per year and is attributed
to the increase in the sensitivity and the speciﬁcity of
noninvasive imaging methods (i.e., CT, MRI, MRA, and
cranial ultrasound studies) and the increased survival rate
duetomoreeﬀectivetreatmentsfordiseaseslikeprematurity,
congenital heart disease, and leukemia that predispose to
stroke [1–4]. Stroke in children and adolescents has diﬀerent
presentation compared to that in adults. The 80–85% of
adultstrokecasesisreportedtobeischemicwhileitisaround
55% in children. The rest is hemorrhagic strokes for both
age groups [5]. Ischemic strokes are thought to be under-
diagnosed in infancy and childhood. It is very important to
increase our knowledge about stroke in children, especially
regarding etiology, outcome, and also possible treatments to
reduce morbidity, mortality, and recurrence [6–13].
One fourth of “stroke in the young” is seen in children.
The incidence of childhood AIS (acute ischemic stroke) is
at least 2.6 per 100,000 children per year [14]. Neonates
make up 25% of paediatric AIS patients and are therefore
at considerably increased risk. In newborns with seizures, 12
to 14% are diagnosed with underlying cerebral infarction.
There is a slight male predominance (60%) in childhood AIS
[15, 16].
In paediatric cases, the diagnosis may be delayed or even
missed. In neonates, AIS often presents only with lethargy
or seizures. In children, the diagnosis of cerebral infarction is
frequentlydelayed.Compared withadults,acutehemiparesis
in children is more likely to be attributed to migraine
headache, seizure, or focal encephalitis than stroke [17].
Subtlesymptomsarelesslikelytobereportedbythechild
or to be attributed to stroke. In the Canadian Registry, chil-
dren with AIS presented most frequently with hemiparesis
(51%),speechdisorder(17%),andseizures(48%).However,
the neurological presentations of AIS are age related. In
infants with in utero AIS, the diagnosis usually becomes
apparent only when pathological early hand dominance
develops between 6 and 12 months of age and leads to a
CT scan [13, 18]. Neonates with acute stroke present with
seizures or lethargy in the ﬁrst few days after birth, and
hemiparesisispresentinlessthan25%atdiagnosis,although
it may develop later [7, 14, 19]. Older infants with AIS2 Stroke Research and Treatment
typically present with an acute focal neurological deﬁcit,
usually hemiparesis. In school-age children, speech deﬁcit
or other subtle signs including sensory or visual deﬁcits
can be recognized. More than 50% of children experience
diﬀuse symptoms accompanying AIS, including headache,
lethargy, or confusion. These symptoms are more common
in younger children [14, 20]. It is important to diﬀerentiate a
postictal hemiparesis from the typically brief Todd’s paresis,
as seizures can be due to AIS [20].
The duration of a neurological deﬁcit in children with
AIS is frequently brief. The classical criteria for stroke in
adults include focal neurological deﬁcit persisting for at least
24 hours. Using these criteria, many AIS events in children
would be missed. In infants focal signs are rare and in
children a very rapid return of neurological function (less
than 1 hour) can be associated with an infarct on the CT
or MRI scan. In the absence of ﬁnding arterial stenosis on
vascular imaging, the diﬀerentiation of transient ischemic
attack (TIA) from migraine or seizure can be diﬃcult.
Recognition of TIAs in children is important, however,
because appropriate antithrombotic therapy can prevent
subsequent AIS [21].
Approximately one half of acute ischemic stroke cases
occur in children with no known risk factors [22]. The
most frequent causes for AIS in childhood are arteriopathies
(ﬁbromuscular dysplasia, moya-moya syndrome), vasospas-
tic disorders (migraine), hemoglobinopathies, leukemia,
acquired prothrombotic states, congenital heart disease,
a n da c q u i r e dh e a r td i s e a s e s[ 21]. Although risk factors in
children with AIS are strikingly diﬀerent from those in
adults,inwhomatherosclerosisistheoverwhelmingetiology,
many of the risk factors being discovered in children with
strokealsoplayanimportantcontributoryroleinadultswith
stroke [15, 23].
The childhood stroke is underdiagnosed due to its
challenging nature. It is in most cases not included in the dif-
ferential diagnosis of acutely ill children. Acute hemiparesis
in children is more likely to be attributed to other causes. It
is of critical value to have accurate diagnosis and to identify
patient-speciﬁc risk factors. As a result, an appropriate
treatment can be initiated fast, systemic complications may
be minimized and a secondary stroke may be prevented [23].
Although the role of laboratory screening in childhood
stroke is not clear, complete blood cell count, iron studies,
PT, PTT sedimentation rate, and antinuclear antibody are
often sent. Hb electrophoresis and urine drug screens, par-
ticularlyforsympathomimetics,maybeindicated[24].Afull
evaluationforthrombophiliaisreasonableinallchildrenand
should include protein C and protein S, antithrombin III,
heparin cofactor II, plasminogen, von Willebrand antigen,
factor VIII, factor XII, factor V Leiden, activated protein C
resistance, prothrombin 20210 gene, serum homocysteine,
methylene-tetra-hydro-folatereductase, lipoprotein (a), and
antiphospholipid antibodies. Apart from the gene studies,
the blood samples should be taken at least 4–6 months after
the insult [25–27].
The optimal method for diagnosis of stroke is MRI
with diﬀusion- and perfusion-weighted imaging. Being a
noninvasive procedureMRangiography(MRA)detectslarge
vascular abnormalities. It is proven to be as eﬀective as
cerebral angiography in detecting large lesions. MR spec-
troscopyanddiﬀusion-weightedimagingwithMRAincrease
the sensitivity of MRI detecting ischemia and infarction [24–
26, 28–30].
As there is no randomized controlled treatment trials
in children with AIS, many of the treatment approaches
increasingly used in children have been adapted from studies
in adults. However, there are age-related diﬀerences in the
hemostatic, vascular, and neurological systems compared
with adults. This must be taken into account while applying
antithrombotic and neuroprotective therapies to children
with AIS. Children with stroke are primarily treated for the
underlying risk factors and prevention of recurrent cerebral
ischemic events [21].
Due to having a negligible risk of recurrence, neonates
with AIS do not require routine antithrombotic treatment.
However, recurrent TIAs and strokes occur in 7 to 20% in
older infants and children with AIS. For these patients, long-
term therapy with ASA is needed to prevent the risk. In
children with cardiogenic AIS, dissection, high-grade steno-
sis of a cerebral artery, severe prothrombotic conditions, or
failure of ASA therapy in preventing recurrence, LMWH
or coumadin is frequently continued for several months.
The risk of recurrent cerebral thrombotic events must be
balanced against the risks of treatment, particularly bleeding
risk [21, 31].
Thrombolytic agents should only be used in the setting
of a clinical trial until safety and feasibility data are available
astheycarryanunknownbutpotentiallyverysigniﬁcantrisk
of hemorrhage in children with AIS [32, 33].
Clinical presentation, underlying cause, size of infarct,
and stroke subtype appear to be inﬂuential factors on the
outcome. Infarct volume greater than 10% of intracranial
volume is associated with worse outcome. Although mortal-
ity among children is lower than in adults, stroke in children
is associated with long-term sequelae. According to the
studies, 55% of children develop sensory or motor problems,
seizure, developmental delay, or cognitive disorders; 15% die
and 35% are neurologically normal [4, 5, 34].
The general rate of stroke recurrence is between 26% and
30%,particularlyduringtheﬁrst6monthspoststroke[28].It
ishigheramong childrenwithidentiﬁed risk factors.Because
of unidentiﬁed risk factors for recurrence or lack of adequate
treatment, idiopathic stroke may have a higher recurrence
than previously believed [1, 35].
There is limited evidence regarding the eﬃcacy of sec-
ondary prevention strategies in childhood stroke; however,
ASA (acetyl salicylic ascit) is widely used. ASA is indicated
forsecondarypreventionofAISinchildrenexceptinpatients
with SCD and those with high risk of recurrence and
severehypercoagulablestate.Althoughtheidealprophylactic
dose is undeﬁned, doses between 1–5mg/kg body weight
per/day have been eﬀective so far. Platelet antiaggregants
are sometimes also used in patients with MMD (Moya
Moya Disease). When the patient is a poor candidate for
surgery or has a relatively mild disease clopidogrel may be
an alternative treatment when long-term therapy with ASA
is contraindicated or not tolerated. Clopidogrel should notStroke Research and Treatment 3
be used in combination with ASA in patients with multiple
risk factors for intracranial hemorrhage and intracranial
vasculopathies [36].
Long-termanticoagulationwithheparinorwarfarinmay
be indicated in patients with congenital or acquired heart
disease, arterial dissection, selected hypercoagulable states,
or recurrence of AIS despite ASA treatment. Some probable
riskfactorsaremodiﬁable[37].Hyperhomocysteinemiamay
respond to supplements of folate, vitamin B6, and vitamin
B12. Patients with lipid abnormalities can be managed with
weight control, dietary modiﬁcations, and/or drug therapy.
Patientswithknowninﬂammatorydisordersorlupusshould
receive disease-speciﬁc treatment [28, 38].
In this study, we presented our experience in the etiology,
risk factors, prophylactic and acute treatment, and the eﬀect
of treatment on recurrence rate in patients who had been
treated for stroke at Pediatric Neurology Department of
Ankara University for 18 years.
2. Methods
The study was designed on retrospective data. The popula-
tion included 108 patients who had been treated for stroke at
Pediatric Neurology Department of Ankara University with
the diagnosis of arterial ischemic stroke between January
1992 and August 2010, and who were younger than 18 years
at the time of the stroke. Forty-one girls (38%) and 67 boys
( 6 2% )w i t hm e a ns y m p t o ma g eo f3 .1 ± 4.04 years (0–18
years old) were followed up in our institution for a mean
period of 4.9 ±3.78 years ( 0–17 years).
The deﬁnition of stroke included the presence of an
acute thrombotic cerebrovascular event that manifested
as hemiplegia, aphasia, visual or balance disturbance, or
seizures. In all patients, the clinical diagnosis of ischemic
strokewasconﬁrmedwithCT,MRI,andmagneticresonance
angiography. Only pediatric stroke cases objectively con-
ﬁrmed by suitable imaging methods were included. Written
informed consent was obtained from the parents of all
patients.
Inclusion criteria were
(1) age 0 days through 18 years,
(2) sudden-onset focal neurological deﬁcit, convulsion
and loss of consciousness,
(3) neuroimaging (CT, MRI) demonstrating recent
ischemia/infarct of arterial or venous distribution,
(4) cerebral/cervical arterial stenosis demonstrated on
MR angiography using a 1.5- or 3-T magnet, CT
angiography, or conventional angiography.
All patients underwent echocardiography and hematologic
investigation (PT, PTT, ﬁbrinogen, protein C, protein S,
antithrombin III, lipoprotein(a), factor VIIIC, factor IX,
homocysteine, and prothrombotic gene mutations (FV
G1691A, PT G20210A, MTHFR C677T )).
The study was approved by the Ankara University Local
Ethics Committee, and informed consent for all blood
samples was obtained from parents of patients before
Table 1: Initial symptoms.
Initial Symptom n/total Percent (%)
hemiparesis or hemiplegoia 70/108 64.8
seizures 37/108 34.2
cranial nerve involvement 2/108 1.8
Postoperative period 1/108 0.9
Headache 5/108 4.6
Fever 3/108 2.7
Intracranial hypertension 3/108 2.7
Dystonia 2/108 1.8
Altered state of consciousness 2/108 1.8
the procedures. Blood samples were taken by peripheral
venipuncture into plastic tubes without any additives and
into plastic tubes containing 1/10 by volume of 3.8%
trisodium citrate. After centrifugation, it is stored at −70◦C.
For genetic analysis, venous blood was obtained in EDTA-
treated sample tubes. The FV G1691A, PT G20210A, and
MTHFR C677T genotypes were determined by polymerase
chain reaction and analysis of restriction fragments as
previously reported [39].
F VIII and F IX were studied with one-stage clotting
assay,andvWfwasstudiedwithimmunoturbidimetricassay.
Factor VIII and factor IX levels were accepted as high if the
value was higher than the cutoﬀ value of 150IU/dl. Protein
C and S were measured with commercially available enzyme-
linked immunosorbent assay kits.
Lipoprotein A was studied by “particle enhanced”
immunonephelometric assay; the reference range was 0–
30ng/mL. For homocysteine, after 12 hours fasting, blood
specimens with EDTA were drawn and measured using
AxSYM homocystein assay(Abbot, Wiesbaden, Germany).
3.StatisticalAnalysis
Statistical analysis of the study was performed using Sta-
tistical Package for Social Sciences (SPSS/PC 13.00). The
data are presented as the mean ± standard deviation (SD).
All categorical data were analyzed with a Chisquare test or
Fisher’s exact test. A P value of equal to, or less than.05, was
considered to indicate statistical signiﬁcance.
4. Results
Hemiparesis or hemiplegia occurred in 54 (50%), hemipare-
sis and seizure in 12 (13%), hemiparesis and cranial nerve
involvementin2(1.9%),andseizuresin23(21.3%)patients.
Five patients presented with headache. Initial symptoms are
shown in Table 1.
The overall distribution of prothrombotic risk factors
and underlying clinical diagnosis are shown in Table 2.
Eleven patients received acute treatment: 7/93 acute
arterial ischemic stroke, 2/8 sinovenous thrombosis, and 2/7
hemorrhagic stroke received acute treatment. Table 3 shows
the drugs that were used in acute treatment.4 Stroke Research and Treatment
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Table 3: The medication in acute treatment.
Medication Acute ischemic stroke n(%) Sinovenous thrombosis n (%) Hemorrhagic stroke n (%)
Unfractionated heparin 4 (%4.3) 2 (%25) —
TPA∗+ Unfractionated Heparin 2 (%2.2) — —
Warfarin 1 (%1.1) — —
K-Vitamin — — 2 (%28.6)
∗ =Tissue plasminogen activator.
Table 4: Medication in prophylaxis.
Medication Acute ischemic stroke n(%) Sinovenous-thrombosis n(%) Hemorrhagic stroke n(%)
Aspirin 7 (%7.5) 2 (%25) —
LMWH∗ 6 (%6.5) 1 (12.5) —
Warfarin 1 (%1.1) — —
∗ = low molecular weight heparin.
A total of 7 patients died during the followup: 2 patients
died from congenital heart disease (one was receiving aspirin
and the other one was receiving LMWH as prophylactic
treatment); one patient with antiphospholipid antibody
syndrome died at the fourth ischemic stroke attack despite
of anticoagulant therapy; the other 4 patients, who were
not receiving prophylactic treatment, died from lymphoma,
leukemia, encephalitis, and congenital heart disease.
17 patients received prophylaxis: 9 patients aspirin, 7
patients LMWH, and 1 patient coumadin. Table 4 shows the
patients on prophylaxis treatment and outcome. Prophylaxis
is given to patients especially with congenital heart disease
and to children who is carrying prothrombotic risk factors.
Table 5 gives the summary of risk factors. Ninetytwo (85%)
patients did not received prophylactic treatment. Except
from the antiplatelet therapy, 4 patients had folate supple-
mentation for hyperhomocysteinemia.
During the follow-up period (mean, 4.9 ± 3.78 years;
range, 0–17 years), recurrence was seen in 4 patients (4.3%).
Apart from one patient who died at the fourth ischemic
strokeattack(underanticoagulanttherapy),onepatientwith
moyamoyadisease,whohadbeenrecruitedatthetimeofthe
second recurrence, received no prophylactic treatment dur-
ing the followup and had no other recurrence. Recurrence
was observed in another patient with elevated lipoprotein
A. However, the patient did not attend the followup. The
fourth patient who had recurrence had Thalassemia major
andhadbonemarrowtransplantationfromhisfatherandhis
MTHFR mutation was heterozygote. He had no recurrence
after prophylaxis.
Table 5 shows prothrombotic risk factors of patients who
received prophylaxis; 7 patients had elevated homocysteine,
5 had factor VIII elevation, 4 had MTHFR homozygote
mutation, 2 had factor V leiden mutation, 3 had protein C
deﬁciency, and 2 had protein S deﬁciency.
Table 6 shows the patients on prophylaxis and the
outcome of these patients. Prophylaxis is given to patients
especially with congenital heart disease and to children
who had ongoing underlying prothrombotic tendency like
antiphospholipid antibody syndrome and renal transplan-
tation and to the patient who is carrying 6 prothrombotic
risk factors. Ninetyone out of 108 (84.3 %) patient did not
received prophylactic treatment. Except from the antiplatelet
therapy, 4 patients had folate supplementation for hyperho-
mocysteinemia.
As a result, recurrence was seen in one patient in the
group of 17 patients with prophylaxis and no patient had
recurrence in the group of 91 patients without prophylaxis.
Intracranial bleeding occured in one patient in the prophy-
laxis group due to aspirin (2mg/kg/day).
As we can see in Table 7, 30 patients had no risk factors,
34 patients had only one risk factor, and 44 patients had
multiple risk factors. Recurrence was seen in three patients;
onewithoutanyriskfactor,onewithonlyoneriskfactor,and
the other patient with multiple risk factors. There was not
any statistical correlation between the recurrence of stroke
and the existence risk factors (P = .961). Seventeen patients
received prophylactic treatment: 2 without any risk factors
(patients with rheumatic heart disease and antiphospholipid
antibody syndrome), 3 had one risk factor, 12 patients had
multiple risk factors. The majority of patients who received
prophylactic treatment had multiple risk factors (There is
statistical correlation. P = .024).
5. Discussion
Given the absence of data from randomized controlled trials,
it is important to acknowledge the rather ﬂimsy evidence,
which is mainly dependent on consensus. This evidence base
can be improved by prospective randomized controlled trials
in paediatric stroke. There are various obstacles to this lofty
aim, one being the low occurrence of childhood stroke and
the need for a large population base in order to provide a
suﬃcient sample size for case-control studies or for trials
of interventions predicted to have a small beneﬁt. Another
challenge is the wide heterogeneity of childhood stroke
aetiologies compared with most adult strokes, in which one
overriding mechanism, atherosclerosis, predominates. The
patientsaetiologies,followedinourclinic,weresimilartothe
literature except sickle cell disease [40, 41].6 Stroke Research and Treatment
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Table 6: Patients who received prophylaxis and outcome.
Basic disease Anticoagulant
therapy Prothrombotic risk factors Outcome
Congenital adrenal
hyperplasia Aspirin
FV Leiden gene mutation in
heterozygous form, MTHFR gene
677 TT homozygous mutation,
elevated FVIII, FIX homocystein,
and lipoprotein(a)
Intracranial bleeding was diagnosed
and the aspirin prophylaxis was
ceased and no recurrence was
observed during the follow-up
period
Antiphospholipid antibody
syndrome
Coumadin,
LMWH
FV Leiden gene mutation, elevated
FIX
Died at the fourth ischemic stroke
attack
Congenital heart disease Aspirin Elevated FVIII, FIX homocystein,
and lipoprotein(a) No recurrence
B12 deﬁciency-related
megaloblastic anemia Aspirin
FV Leiden gene mutation MTHFR
gene 677 TT mutation, elevated F
VIII, and homocystein
No recurrence
Congenital heart disease Aspirin MTHFR gene 677 TT mutation,
elevated F VIII, and homocystein No recurrence
Protein S deﬁciency-related
sinus venous thrombosis LWMH Protein S deﬁciency, elevated
triglyceride No recurrence
Congenital heart disease Aspirin No recurrence
Moyamoya Aspirin MTHFR gene 677 TT homozygous
mutation, elevated homocystein No recurrence
Protein S deﬁciency related
sinus venous thrombosis LMWH Protein S deﬁciency, elevated F VIII No recurrence
˙ Idiopathic LMWH
MTHFR gene 677 TT homozygous
mutation, activated protein C
resistance
No recurrence
Receiving cyclosporine for
renal transplantation LMWH No recurrence
Bone marrow
transplantation for beta
thalassemia major
LMWH MTHFR gene 677 TT homozygous
mutation, elevated homocystein Recurrence∗
˙ Idiopathic Aspirin MTHFR gene 677 TT mutation No recurrence
Congenital heart disease Aspirin Protein C deﬁciency Died from congenital heart disease
Congenital heart disease LMWH Elevated homocystein, protein C,
and AT III deﬁciency Died from congenital heart disease
Rheumatismal heart disease
related prosthetic valve Coumadin No recurrence
Down syndrome and
congenital heart disease Coumadin Elevated homocystein, FVIII, FIX No recurrence
∗prophylaxis was given after recurrence.
Table 7: Recurrence and risk factor relation.
Risk factor No. of recurrences recurrence Total
None 29 1 30
One risk factor 33 1 34
multiple risk factors 43 1 44
Total 105 3 108
Aetiologies can predict treatment eﬀect to a large extent;
hence, subgroups of more homogenous patients will need to
be studied in some cases. An important issue is the diﬃculty
in recognizing vascular pathologies in children with diverse
presentations, such as coma, seizures, and hemiparesis. One
of the most eﬀective interventions to improve outcomes in
adults who had stroke is the reorganization of services into
specialiststrokeunits.However,thesmallnumberofpatients
with stroke in most paediatric centres creates a challenge for
building up such specialized units [42].
As acute treatment recommendations in the guidelines
are restricted, 11 patients received acute treatment: 7/93
acute ischemic infarct, 2/8 sinovenous thrombosis, and 2/7
hemorrhagic stroke received acute treatment. Only one
patient with antiphospholipid antibody syndrome died at
the fourth ischemic stroke attack despite of anticoagulant
therapy.
The role of antiplatelet therapy is well established in
adultarteriovasculardisease.Theprevalenceofthesediseases
has prompted the search for “a Better aspirin”, and new
targets for antiplatelet therapy are being actively sought.8 Stroke Research and Treatment
Currently,theuseofantiplatelettherapyinpaediatricdisease
is signiﬁcantly limited.
NeonateswithAISdonotrequireroutineantithrombotic
treatment because they have a negligible risk of recurrence.
However, in older infants and children with AIS, long-term
therapy with ASA is needed to prevent recurrent TIAs and
strokes, which occur in 7 to 20% of patients. In children
with cardiogenic AIS, dissection, high-grade stenosis of a
cerebralartery,severeprothromboticconditions,orfailureof
ASAtherapyinpreventingrecurrence,LMWH,orcoumadin
is frequently continued for several months. The risk of
recurrent cerebral thrombotic events must be balanced
against the risks of treatment, particularly bleeding risk.
Thrombolytic agents carry an unknown but potentially very
signiﬁcant risk of hemorrhage in children with AIS, and
should only be used in the setting of a clinical trial until
safety and feasibility data are available. And in our study
Intracranial bleeding was occured in one patient in the
prophylaxis group due to aspirin.
Related literature (Lynch, Fullerton, Lanthier, and oth-
ers) points to a varying rate of stroke recurrence which is
between26%and30%,particularlyduringtheﬁrst6months
after stroke and is higher among children with identiﬁed risk
factors [21, 22, 43]. While following our patients, we utilize
the guidelines and the majority of the patients who received
prophylactic treatment had multiple risk factors [37]. We
had seen 3 recurrences, one without any risk factor. There
has not been any recurrence in the group of patients who
received prophylactic medication since we always consider
to provide prophylaxis for eligible patients. However, the
physicianswhoarefollowingstrokeinpediatricagemustpay
attention to the stroke patients who had no risk factors for
recurrence.
Long-term followup for children is better than for
adults. Most of our patients achieved an age-appropriate
independency. The use of antithrombotic therapy appears to
be increasing in pediatric AIS, as almost all children were
independent at followup.
6. Conclusion
Stroke among children is a rare disease. However, signiﬁcant
morbidity and mortality have been identiﬁed. Stroke should
be included in the diﬀerential diagnosis of any child pre-
senting new-onset focal deﬁcits, altered speech, or disequi-
librium and be thoroughly investigated. Advanced imaging
techniques have improved the diagnosis and understanding
of paediatric stroke. Studies to determine the optimal acute
treatment of childhood stroke and secondary prevention
and risk factor modiﬁcation are of critical importance and
urgently needed. Until prospective randomized data on
chronic anticoagulation in pediatric patients are available,
pediatric patients should be treated on an individual basis.
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